Financial Instruments and Fair Value Measurements - Additional Information (Detail) - USD ($)	3 Months Ended	12 Months Ended
	Sep. 30, 2015	Sep. 30, 2015	Sep. 30, 2014	Jun. 30, 2015	Dec. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Remaining cash equivalents	$ 1,277,000,000	$ 1,277,000,000	$ 821,000,000
Fair value of long-term debt	11,600,000,000	11,600,000,000	4,100,000,000
Transfer of assets in and out of level 1, 2 and 3 measurements during the period		0	0
Transfer of liabilities in and out of level 1, 2 and 3 measurements during the period		0	$ 0
Asset Impairment Charges	72,000,000
Gen Cell Biosystems
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of contingent consideration					$ 36,000,000
Cellular Research
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of contingent consideration	28,000,000	28,000,000
Notes Due June 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, face amount	750,000,000	750,000,000		$ 750,000,000
Fair value of debt classified from long term to short term	$ 750,000,000	$ 750,000,000
Minimum
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Maturity period of short-term investments at the time of purchase		3 months
Maximum
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Maturity period of short-term investments at the time of purchase		1 year